BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BCMA-targeted LCAR-BCDR Cells Product in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: Nanjing Legend Biotech Co.
Terminated
Per sponsor request
Other terminated trials from Nanjing Legend Biotech Co.
- Advanced Gastrointestinal Tumors · Phase PHASE1 · Oct 2025
- Relapsed and Refractory B-cell Non-Hodgkin Lymphoma · Phase PHASE1 · Aug 2025
- Solid Tumors, Adult · Phase PHASE1 · Jul 2023
- Lymphoma, B-Cell · Phase PHASE1 · May 2021
- Acute Leukemia · Phase PHASE1 · Jul 2019
More terminations from Nanjing Legend Biotech Co.
Other Relapsed/Refractory Multiple Myeloma trials with similar outcome
This PHASE1 trial investigates Relapsed/Refractory Multiple Myeloma and is currently terminated or withdrawn. Nanjing Legend Biotech Co. leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Aug 2025 — Present [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Sep 2024 — Aug 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Jan 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nanjing Legend Biotech Co.
- Weijun Fu
For direct contact, visit the study record on ClinicalTrials.gov .